Infections due to non-neoformans cryptococcal species.
The incidence of infections due to non-neoformans cryptococcal species is increasing. Risk factors associated with infections due to these organisms include immunosuppression and clinical syndromes are similar to those encountered with Cryptococcus neoformans. Therapy with antifungal agents is often successful.
McCurdy
Lewis H
LH
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, Md., USA.
Morrow
Jason D
JD
D000666:Amphotericin B / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D003453:Cryptococcosis / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology; D003454:Cryptococcus / Q000145:classification* / Q000187:drug effects*; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D015725:Fluconazole / Q000627:therapeutic use; D005437:Flucytosine / Q000627:therapeutic use; D006801:Humans
D000935:Antifungal Agents; D000666:Amphotericin B; D015725:Fluconazole; D005437:Flucytosine